This means that the development of non-invasive techniques for tumor genotyping has remained at the forefront of cancer research for some time, resulting in the identification of the circulating tumor DNA (ctDNA) assays used in EGFR typing and NSCLC evaluations, which rely on the DNA released from circulating tumor cells for analysis [12,13,14,15]. This evidence concerns the gene EGFR and cancer.